Received May 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | J3952 | — |
Engerix-B second adult dose administration to a pediatric patient; adult dose of Engerix-B to an 11-year-old patient as a second dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult product administered to child in a 11-year-old female patient who received HBV (Engerix B) (batch number J3952, expiry date 01-DEC-2026) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine on unknown date). On 30-SEP-2024, the patient received the 2nd dose of Engerix B. On 30-SEP-2024, an unknown time after receiving Engerix B, the patient experienced adult product administered to child (Verbatim: Engerix-B second adult dose administration to a pediatric patient) and overdose (Verbatim: adult dose of Engerix-B to an 11-year-old patient as a second dose). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 23-MAY-2025 The medical assistant asked for side effects and how to proceed with the third dose after giving an adult dose of Engerix-B to an 11-year-old patient as a second dose, which led to adult product administered to child and overdose. On 30th September 2024 the patient correctly received the first pediatric dose. The Vaccine Administration Facility is the same as Primary Reporter.